Published in Curr Ophthalmol Rep on February 02, 2017
A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study. Ophthalmology (2012) 3.24
The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol (1992) 3.18
Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ (1999) 2.65
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med (2004) 2.64
Long-term results of deep anterior lamellar versus penetrating keratoplasty. Ophthalmology (2011) 2.50
Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol (2012) 2.14
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci (2007) 2.05
Graft failure after penetrating keratoplasty. Surv Ophthalmol (1990) 2.02
Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology (1994) 2.01
Corneal graft rejection. Surv Ophthalmol (2007) 1.96
Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med (2002) 1.79
Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation (2001) 1.74
Effect of donor epithelium on corneal transplant survival. Ophthalmology (1988) 1.72
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol (2009) 1.60
Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis. Cornea (2013) 1.58
Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea (2008) 1.54
Corneal antigen-presenting cells. Chem Immunol Allergy (2007) 1.53
Oral immunisation as a strategy for enhancing corneal allograft survival. Br J Ophthalmol (1997) 1.51
Topical cyclosporine in high-risk corneal transplants. Ophthalmology (1989) 1.43
Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol (2008) 1.27
Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology (1994) 1.26
Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. Transpl Immunol (1996) 1.26
Graft failure IV. Immunologic mechanisms of corneal transplant rejection. Int Ophthalmol (2008) 1.25
Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol (2001) 1.23
Penetrating keratoplasty in children. Ophthalmology (1984) 1.18
Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (2009) 1.18
The profile of repeated corneal transplantation. Ophthalmology (2001) 1.17
Corneal graft outcome study. Cornea (2001) 1.13
Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med (1986) 1.11
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08
Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation (2005) 1.07
Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology (1987) 1.06
Effect of donor and recipient factors on corneal graft rejection. Cornea (2012) 1.05
Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int (2005) 1.02
Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol (2002) 1.00
Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea (1993) 1.00
Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci (2006) 0.99
Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea (2012) 0.96
VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation. Transplantation (2015) 0.96
Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond) (1995) 0.95
Corneal graft rejection 10 years after penetrating keratoplasty in the cornea donor study. Cornea (2014) 0.94
Factors associated with corneal graft survival in the cornea donor study. JAMA Ophthalmol (2015) 0.94
Severing corneal nerves in one eye induces sympathetic loss of immune privilege and promotes rejection of future corneal allografts placed in either eye. Am J Transplant (2015) 0.94
Outcomes after DSEK in 101 eyes with previous trabeculectomy and tube shunt implantation. Cornea (2014) 0.93
Effects of local and systemic viral interleukin-10 gene transfer on corneal allograft survival. Gene Ther (2006) 0.92
Negative effect of HLA-DR matching on corneal transplant rejection. Transplant Proc (1995) 0.92
HLA-DR matching in corneal transplantation. Systematic review of published evidence. Corneal Transplant Follow-up Study Collaborators. Transplantation (1995) 0.92
Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol (2000) 0.92
Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty. Am J Ophthalmol (2012) 0.91
'Chimeric' grafts assembled from multiple allodisparate donors enjoy enhanced transplant survival. Am J Transplant (2009) 0.90
Sunitinib inhibits inflammatory corneal lymphangiogenesis. Invest Ophthalmol Vis Sci (2013) 0.90
Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea (2011) 0.89
Deletion of the chemokine receptor CCR1 prolongs corneal allograft survival. Invest Ophthalmol Vis Sci (2007) 0.88
Lymph node removal enhances corneal graft survival in mice at high risk of rejection. BMC Ophthalmol (2004) 0.88
Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection. Transplantation (2009) 0.87
Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol (2006) 0.87
A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea (1994) 0.87
Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol (2001) 0.87
Management of vernal keratoconjunctivitis. Ophthalmol Ther (2013) 0.86
Large-diameter penetrating keratoplasty: indications and outcomes. Cornea (2010) 0.86
Differential chemokine gene expression in corneal transplant rejection. Invest Ophthalmol Vis Sci (1999) 0.85
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea (2016) 0.85
Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis. Cornea (2011) 0.84
[Cyclosporin A eyedrops in the prevention of high-risk corneal graft rejection. II. Postoperative clinical results]. J Fr Ophtalmol (1987) 0.84
Expression of cell adhesion molecules in corneal graft failure. Cornea (1993) 0.84
Matching for Human Leukocyte Antigens (HLA) in corneal transplantation - to do or not to do. Prog Retin Eye Res (2015) 0.84
The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model. Eur J Ophthalmol (2013) 0.83
Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat. Transplantation (1998) 0.83
The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure. Am J Transplant (2016) 0.83
Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol (2010) 0.83
Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol (2012) 0.82
Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival. Am J Transplant (2012) 0.82
Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model. Invest Ophthalmol Vis Sci (2012) 0.82
Prevention and treatment of corneal graft rejection: current practice patterns of the Cornea Society (2011). Cornea (2015) 0.82
Corneal Allograft Rejection: Immunopathogenesis to Therapeutics. J Clin Cell Immunol (2013) 0.81
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in the conjunctiva--a potential link between lymphangiogenesis and leukocyte trafficking on the ocular surface. Adv Exp Med Biol (2002) 0.81
Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol (2000) 0.81
Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf (2008) 0.80
Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. Cornea (2014) 0.80
Keratoplasty postoperative treatment update. Cornea (2013) 0.80
Topical cyclosporine in corneal transplantation. Cornea (2015) 0.79
Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression. Cornea (2015) 0.79
The role of minor histocompatibility alloantigens in penetrating keratoplasty. Dev Ophthalmol (2003) 0.79
Local or short-term systemic costimulatory molecule blockade prolongs rat corneal allograft survival. Clin Experiment Ophthalmol (2005) 0.79
Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Exp Eye Res (1997) 0.78
Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Cornea (2010) 0.78
[Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study]. Klin Monbl Augenheilkd (2008) 0.78
Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival. Int Ophthalmol (2014) 0.78
Effects of subconjunctival ranibizumab in a presensitized rat model of corneal graft. Exp Eye Res (2012) 0.77
Long-term results of keratoplasty in patients with herpes zoster ophthalmicus. Cornea (2013) 0.77
Monoclonal antibody to ICAM-1 prolongs murine heterotopic corneal allograft survival. Aust N Z J Ophthalmol (1991) 0.76
Gene therapy approaches to prevent corneal graft rejection: where do we stand? Ophthalmic Res (2013) 0.76
Corneal allograft reaction and its relationship to suture site neovascularization. Ophthalmic Surg (1977) 0.76
The role of cell adhesion molecules in allograft rejection after penetrating keratoplasty in mice. Clinical and immunohistochemical study. Graefes Arch Clin Exp Ophthalmol (1996) 0.76
Significant effect of high-resolution HLA-DRB1 matching in high-risk corneal transplantation. Transplantation (1996) 0.76
Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection. Yan Ke Xue Bao (2002) 0.76
Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model. Cutan Ocul Toxicol (2013) 0.76
A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab. Cornea (2012) 0.76
Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefes Arch Clin Exp Ophthalmol (2014) 0.76
Systemic cyclosporine and corneal transplantation. Int Ophthalmol (2016) 0.76
Medically reversible limbal stem cell disease: clinical features and management strategies. Ophthalmology (2014) 0.79